Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
CONCLUSIONS: Trabectedin is a safe and effective drug for treating advanced STS. Our results reflect real-life data with patients receiving the drug as a third and even fourth line of treatment, or with a suboptimal performance status, yet achieving impressive clinical benefit rates and survival.
PMID: 30324774 [PubMed - in process]
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
More News: Chemotherapy | General Medicine | Israel Health | Leiomyosarcoma | Liposarcoma | Middle East Health | Sarcomas | Soft Tissue Sarcoma | Statistics | Study | Toxicology